To AMGEN investors who are not interested in alternatives - apologies for the intrusion.
This is the last weekly update before the (Tuesday evening) data capture point upon which the reconstitution of the Russell Indexes will be based this year.
Last year the minimum capitalization within the Russell 3000 was $112,000,000 - surely nothing short of a massive sell-off on Tuesday could prevent Insmed's inclusion -
Market cap appreciation over the last ten weeks (end of day) -
May 27 ..... $260,945,670
May 20 ..... $224,696,320
May 13 ..... $206,571,640
May 06 ..... $203,343,960
Apr 29 ..... $216,254,690
Apr 21 ..... $238,103,610
Apr 15 ..... $217,247,820
Apr 08 ..... $190,681,520
Apr 01 ..... $180,750,190
Mar 25 ..... $153,687,310
Mar 18 ..... $116,444,830
Market cap appreciation leading up to Insmed's previous inclusion in 2009 (high of day) -
June 19 ..... $324,277,460 (peak capitalization)
June 12 ..... $272,544,480
June 05 ..... $240,999,980
May 29 ..... $223,335,060 (data capture point for Index reconstitution)
May 22 ..... $211,979,040
May 15 ..... $172,863,860
May 08 ..... $189,267,000
May 01 ..... $189,267,000
Apr 24 ..... $161,507,840
Apr 17 ..... $151,413,600
Apr 09 ..... $119,869,100
Apr 03 ..... $117,345,540
The Company would appear to be in a far stronger position this year -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=927&tid=140906&mid=140906&tof=1&frt=2
If Insmed does qualify for inclusion on Tuesday evening the buyers for the funds which track the Russell Indexes will have until June 24 (a further eighteen trading days) in which to accumulate the required shares -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=586289&mid=586293&tof=351&rt=2&frt=2&off=1
This will doubtless be perceived by many investors as little more than the opportunity to make a quick profit by buying in before the fund accumulation drives the price to a higher level - but one suspects that the smart money sees far more here than the immediate opportunity -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=588859&mid=588859&tof=26&frt=2
Further reading -
Ten reasons to be a shareholder -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=583014&mid=583014&tof=3&frt=2
Could Arikace revenue deliver a leading biotech market cap? -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=586233&mid=586233&tof=28&frt=2
The NTM opportunity may be far larger than projected -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=588079&mid=588079&tof=77&frt=2
Potential competition for Arikace? -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=574210&mid=574210&tof=3&frt=2
A high-profile presentation during the 'fund accumulation' period in June -
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_I/threadview?bn=9585&tid=586821&mid=586894
Could Phase III efficacy alone trigger a major move? -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=585439&mid=585439&tof=-1&rt=2&frt=2&off=1
The bigger picture -
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=9585&tid=574326&mid=574326&tof=18&frt=2